After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

First Quarter 2025 Results Key Financial Results Revenue: CA$960.9m (up 7.8% from 1Q ...

Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

IGM Financial Inc (IGIFF) reports record earnings and significant asset growth, while navigating market volatility and strategic challenges.

US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows.

Shares Expanded Tech Sector has seen a significant rebound but remains fairly valued with a mixed technical outlook. Learn ...

IGM Financial Inc. reported adjusted net earnings of $237.8 million for the first quarter, up 5.9% from the same quarter of ...

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows. The new molecule combines the specificity of a mature flu fighter with the ...

IGM Financial Inc. reported its Q1 2025 earnings, revealing an adjusted earnings per share (EPS) of $1.00, falling short of analysts’ forecast of $1.05. The company’s revenue also missed expectations, ...

May 8 - IGM Biosciences: Sanofi's termination of its 2022 collab with IGM Biosciences was the final nail in the coffin for the biotech’s research, given that it represented the last program in ...